Article Text

Download PDFPDF

PS5:103 Costimulatory maker on cytotoxic cd8+ t-cells in patients with sle
  1. C Oster1,
  2. B Wilde1,
  3. K Hübbers1,
  4. A Kribben1,
  5. O Witzke2 and
  6. S Dolff2
  1. 1Department of Nephrology, University Hospital Essen, Germany
  2. 2Department of Infectious Diseases, University Hospital Essen, Germany


Background Systemic lupus erythematodes (SLE) is an autoimmune disease where T-cell dependent B-cell activation plays a crucial role. Costimulatory marker promote and inhibit immune responses after ligation. Here we analysed the marker BTLA (CD272), PD-1 (CD279), HLA-DR and HVEM on peripheral cyctotoxic T-cells.

Patients and methods 30 SLE-patients fulfilling the American College of Rheumatology (ACR) criteria für SLE and 14 healthy controls (HC) were enrolled. Whole blood staining was performed and samples were analysed by multi-colour flow cytometry. Disease activity was assessed by SLEDAI. Renal involvement was defined as biopsy proven lupus nephritis.

Results The expression of the costimulatory marker PD-1 is signifcantly increased on CD8 +T cells in SLE patients as compared to with healthy controls (31.3%±26.7% vs 15.63%±12.22%). We could not found a significant difference in the expression levels of the BTLA receptor on CD8 +T cells (72,24%±15.33 vs 72.66%±9,4%) in SLE patients as compared to with healthy controls. Also HLA-DR and HVEM was not significantly different expressed on CD8 +T cells in SLE.

Conclusions The costimulytory maker PD-1 is upregualted on cytotoxic T-cells in SLE. Further investigations are needed to elucidate the functional role of this pattern.

  • PD-1
  • BTLA-4
  • CD8 T-cell

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.